
    
      This was a multi-center, non-randomized, open-label study in patients with high-risk
      neuroblastoma to assess the immunogenicity, safety and tolerability of Unituxin combination
      therapy. Patients enrolled in the study were prescribed Unituxin for the treatment of
      high-risk neuroblastoma.
    
  